Aicuris Anti-Infective Cures Ag

Aicuris Anti-Infective Cures Ag company information, Employees & Contact Information

AiCuris is meeting the needs of the growing population of immunocompromised people who require precise therapies to effectively treat infection. Our flagship product, PREVYMIS, marketed by our partner MSD, treats CMV in a defined group of transplant recipients. Our pivotal phase 3 candidate Pritelivir is designed to address recurrent and resistant HSV infections in a broad population of patients with weakened immune systems. For immunocompromised people, an otherwise manageable infection can mean life or death. AiCuris, with its expertise and growing pipeline, is committed to providing therapeutic solutions for them now and in the future.

Company Details

Employees
76
Founded
-
Address
Friedrich-Ebert-Strasse 475, Building 302,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Wuppertal, NRW
Looking for a particular Aicuris Anti-Infective Cures Ag employee's phone or email?

Aicuris Anti-Infective Cures Ag Questions

News

Aicuris antiviral scores in phase 3 HSV trial, setting up FDA filing - Fierce Biotech

Aicuris antiviral scores in phase 3 HSV trial, setting up FDA filing Fierce Biotech

Aicuris Presents Positive Phase 2 Results for Pritelivir and Favorable Phase 1 Safety Data for AIC468 at ID Week 2025 - GlobeNewswire

Aicuris Presents Positive Phase 2 Results for Pritelivir and Favorable Phase 1 Safety Data for AIC468 at ID Week 2025 GlobeNewswire

Aicuris Enrolled Last Participant in Pivotal Trial with Pritelivir to Treat Refractory Herpes Simplex Infection in Immunocompromised Patients - Yahoo! Finance UK

Aicuris Enrolled Last Participant in Pivotal Trial with Pritelivir to Treat Refractory Herpes Simplex Infection in Immunocompromised Patients Yahoo! Finance UK

Discovery of AIC263282, a Hepatitis B Virus Capsid Assembly Modulator Ready for Candidate Profiling - ACS Publications

Discovery of AIC263282, a Hepatitis B Virus Capsid Assembly Modulator Ready for Candidate Profiling ACS Publications

Aicuris Announces Pritelivir Met Primary Endpoint in - GlobeNewswire

Aicuris Announces Pritelivir Met Primary Endpoint in GlobeNewswire

Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress - Yahoo! Finance UK

Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress Yahoo! Finance UK

Advancing antiviral therapeutics for immunocompromised populations - Drug Target Review

Advancing antiviral therapeutics for immunocompromised populations Drug Target Review

AiCuris commences Phase I trial of AIC468 for BK virus treatment - Clinical Trials Arena

AiCuris commences Phase I trial of AIC468 for BK virus treatment Clinical Trials Arena

Aicuris to file pritelivir NDA on positive phase III data in herpes infections - BioWorld MedTech

Aicuris to file pritelivir NDA on positive phase III data in herpes infections BioWorld MedTech

AiCuris Initiates First-in-Human Phase 1 Trial With Antiviral Agent AIC468 to Address BK Virus Infections in Kidney Transplant Recipients - BioSpace

AiCuris Initiates First-in-Human Phase 1 Trial With Antiviral Agent AIC468 to Address BK Virus Infections in Kidney Transplant Recipients BioSpace

Aicuris Announces Upcoming Oral and Poster Presentations at ID Week 2025 - GlobeNewswire

Aicuris Announces Upcoming Oral and Poster Presentations at ID Week 2025 GlobeNewswire

AiCuris and Hybridize close licensing deal related to BK virus program - drugdiscoverytrends.com

AiCuris and Hybridize close licensing deal related to BK virus program drugdiscoverytrends.com

Phase III Success For AiCuris’s Herpes Simplex Treatment - Citeline News & Insights

Phase III Success For AiCuris’s Herpes Simplex Treatment Citeline News & Insights

AiCuris Announces Milestone Achievements Further Validating its Pipeline of Anti-viral Solutions for Immunocompromised Patients - Business Wire

AiCuris Announces Milestone Achievements Further Validating its Pipeline of Anti-viral Solutions for Immunocompromised Patients Business Wire

Aicuris licences antisense RNA know-how from Hybridize Therapeutics - European Biotechnology Magazine

Aicuris licences antisense RNA know-how from Hybridize Therapeutics European Biotechnology Magazine

Aicuris to focus on anti-infectives for immunocompromised patients - BioWorld MedTech

Aicuris to focus on anti-infectives for immunocompromised patients BioWorld MedTech

AiCuris 'sharpens strategic focus' to immune-compromised at expense of other programs - Fierce Biotech

AiCuris 'sharpens strategic focus' to immune-compromised at expense of other programs Fierce Biotech

Potential Herpes Cure from Germany Fast-Tracked for Patients with Weak Immune Systems - Labiotech.eu

Potential Herpes Cure from Germany Fast-Tracked for Patients with Weak Immune Systems Labiotech.eu

Lacosamide cardiac safety: a thorough QT/QTc trial in healthy volunteers - Wiley Online Library

Lacosamide cardiac safety: a thorough QT/QTc trial in healthy volunteers Wiley Online Library

Merck secures AiCuris's portfolio for $142m - - Global Corporate Venturing

Merck secures AiCuris's portfolio for $142m - Global Corporate Venturing

AiCuris Raises €55M to Continue Phase II Trials of Cytomegalovirus Drug Candidate - Genetic Engineering and Biotechnology News

AiCuris Raises €55M to Continue Phase II Trials of Cytomegalovirus Drug Candidate Genetic Engineering and Biotechnology News

Top Aicuris Anti-Infective Cures Ag Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant